1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Geographic Atrophy Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Above 60 Years
1.2.3 Above 75 Years
1.3 Market by Application
1.3.1 Global Geographic Atrophy Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Late-stage (Phase III)
1.3.3 Phase II
1.3.4 Phase I
1.3.5 Pre-clinical stage
1.4 Study Objectives
1.5 Years Considered 2 Global Growth Trends
2.1 Global Geographic Atrophy Market Perspective (2017-2028)
2.2 Geographic Atrophy Growth Trends by Region
2.2.1 Geographic Atrophy Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Geographic Atrophy Historic Market Size by Region (2017-2022)
2.2.3 Geographic Atrophy Forecasted Market Size by Region (2023-2028)
2.3 Geographic Atrophy Market Dynamics
2.3.1 Geographic Atrophy Industry Trends
2.3.2 Geographic Atrophy Market Drivers
2.3.3 Geographic Atrophy Market Challenges
2.3.4 Geographic Atrophy Market Restraints 3 Competition Landscape by Key Players
3.1 Global Top Geographic Atrophy Players by Revenue
3.1.1 Global Top Geographic Atrophy Players by Revenue (2017-2022)
3.1.2 Global Geographic Atrophy Revenue Market Share by Players (2017-2022)
3.2 Global Geographic Atrophy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Geographic Atrophy Revenue
3.4 Global Geographic Atrophy Market Concentration Ratio
3.4.1 Global Geographic Atrophy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Geographic Atrophy Revenue in 2021
3.5 Geographic Atrophy Key Players Head office and Area Served
3.6 Key Players Geographic Atrophy Product Solution and Service
3.7 Date of Enter into Geographic Atrophy Market
3.8 Mergers & Acquisitions, Expansion Plans 4 Geographic Atrophy Breakdown Data by Type
4.1 Global Geographic Atrophy Historic Market Size by Type (2017-2022)
4.2 Global Geographic Atrophy Forecasted Market Size by Type (2023-2028) 5 Geographic Atrophy Breakdown Data by Application
5.1 Global Geographic Atrophy Historic Market Size by Application (2017-2022)
5.2 Global Geographic Atrophy Forecasted Market Size by Application (2023-2028) 6 North America
6.1 North America Geographic Atrophy Market Size (2017-2028)
6.2 North America Geographic Atrophy Market Size by Country (2017-2022)
6.3 North America Geographic Atrophy Market Size by Country (2023-2028)
6.4 United States
6.5 Canada 7 Europe
7.1 Europe Geographic Atrophy Market Size (2017-2028)
7.2 Europe Geographic Atrophy Market Size by Country (2017-2022)
7.3 Europe Geographic Atrophy Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries 8 Asia-Pacific
8.1 Asia-Pacific Geographic Atrophy Market Size (2017-2028)
8.2 Asia-Pacific Geographic Atrophy Market Size by Country (2017-2022)
8.3 Asia-Pacific Geographic Atrophy Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia 9 Latin America
9.1 Latin America Geographic Atrophy Market Size (2017-2028)
9.2 Latin America Geographic Atrophy Market Size by Country (2017-2022)
9.3 Latin America Geographic Atrophy Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil 10 Middle East & Africa
10.1 Middle East & Africa Geographic Atrophy Market Size (2017-2028)
10.2 Middle East & Africa Geographic Atrophy Market Size by Country (2017-2022)
10.3 Middle East & Africa Geographic Atrophy Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE 11 Key Players Profiles
11.1 Apellis Pharmaceuticals
11.1.1 Apellis Pharmaceuticals Company Detail
11.1.2 Apellis Pharmaceuticals Business Overview
11.1.3 Apellis Pharmaceuticals Geographic Atrophy Introduction
11.1.4 Apellis Pharmaceuticals Revenue in Geographic Atrophy Business (2017-2022)
11.1.5 Apellis Pharmaceuticals Recent Development
11.2 Iveric Bio
11.2.1 Iveric Bio Company Detail
11.2.2 Iveric Bio Business Overview
11.2.3 Iveric Bio Geographic Atrophy Introduction
11.2.4 Iveric Bio Revenue in Geographic Atrophy Business (2017-2022)
11.2.5 Iveric Bio Recent Development
11.3 Alkeus Pharmaceuticals
11.3.1 Alkeus Pharmaceuticals Company Detail
11.3.2 Alkeus Pharmaceuticals Business Overview
11.3.3 Alkeus Pharmaceuticals Geographic Atrophy Introduction
11.3.4 Alkeus Pharmaceuticals Revenue in Geographic Atrophy Business (2017-2022)
11.3.5 Alkeus Pharmaceuticals Recent Development
11.4 Hemera Biosciences
11.4.1 Hemera Biosciences Company Detail
11.4.2 Hemera Biosciences Business Overview
11.4.3 Hemera Biosciences Geographic Atrophy Introduction
11.4.4 Hemera Biosciences Revenue in Geographic Atrophy Business (2017-2022)
11.4.5 Hemera Biosciences Recent Development
11.5 Allegro Ophthalmics
11.5.1 Allegro Ophthalmics Company Detail
11.5.2 Allegro Ophthalmics Business Overview
11.5.3 Allegro Ophthalmics Geographic Atrophy Introduction
11.5.4 Allegro Ophthalmics Revenue in Geographic Atrophy Business (2017-2022)
11.5.5 Allegro Ophthalmics Recent Development
11.6 Stealth BioTherapeutics
11.6.1 Stealth BioTherapeutics Company Detail
11.6.2 Stealth BioTherapeutics Business Overview
11.6.3 Stealth BioTherapeutics Geographic Atrophy Introduction
11.6.4 Stealth BioTherapeutics Revenue in Geographic Atrophy Business (2017-2022)
11.6.5 Stealth BioTherapeutics Recent Development
11.7 Gyroscope Therapeutics
11.7.1 Gyroscope Therapeutics Company Detail
11.7.2 Gyroscope Therapeutics Business Overview
11.7.3 Gyroscope Therapeutics Geographic Atrophy Introduction
11.7.4 Gyroscope Therapeutics Revenue in Geographic Atrophy Business (2017-2022)
11.7.5 Gyroscope Therapeutics Recent Development
11.8 Regenerative Patch Technologies
11.8.1 Regenerative Patch Technologies Company Detail
11.8.2 Regenerative Patch Technologies Business Overview
11.8.3 Regenerative Patch Technologies Geographic Atrophy Introduction
11.8.4 Regenerative Patch Technologies Revenue in Geographic Atrophy Business (2017-2022)
11.8.5 Regenerative Patch Technologies Recent Development
11.9 Roche
11.9.1 Roche Company Detail
11.9.2 Roche Business Overview
11.9.3 Roche Geographic Atrophy Introduction
11.9.4 Roche Revenue in Geographic Atrophy Business (2017-2022)
11.9.5 Roche Recent Development
11.10 Gensight Biologics
11.10.1 Gensight Biologics Company Detail
11.10.2 Gensight Biologics Business Overview
11.10.3 Gensight Biologics Geographic Atrophy Introduction
11.10.4 Gensight Biologics Revenue in Geographic Atrophy Business (2017-2022)
11.10.5 Gensight Biologics Recent Development
11.11 NGM Biopharmaceuticals
11.11.1 NGM Biopharmaceuticals Company Detail
11.11.2 NGM Biopharmaceuticals Business Overview
11.11.3 NGM Biopharmaceuticals Geographic Atrophy Introduction
11.11.4 NGM Biopharmaceuticals Revenue in Geographic Atrophy Business (2017-2022)
11.11.5 NGM Biopharmaceuticals Recent Development
11.12 AstraZeneca
11.12.1 AstraZeneca Company Detail
11.12.2 AstraZeneca Business Overview
11.12.3 AstraZeneca Geographic Atrophy Introduction
11.12.4 AstraZeneca Revenue in Geographic Atrophy Business (2017-2022)
11.12.5 AstraZeneca Recent Development
11.13 Lineage Cell Therapeutics
11.13.1 Lineage Cell Therapeutics Company Detail
11.13.2 Lineage Cell Therapeutics Business Overview
11.13.3 Lineage Cell Therapeutics Geographic Atrophy Introduction
11.13.4 Lineage Cell Therapeutics Revenue in Geographic Atrophy Business (2017-2022)
11.13.5 Lineage Cell Therapeutics Recent Development
11.14 Allergan
11.14.1 Allergan Company Detail
11.14.2 Allergan Business Overview
11.14.3 Allergan Geographic Atrophy Introduction
11.14.4 Allergan Revenue in Geographic Atrophy Business (2017-2022)
11.14.5 Allergan Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
